Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Algernon Pharmaceuticals Inc.
C.AGN
Alternate Symbol(s):
AGNPF
Consumer Cyclical
Healthcare
Advertising Agencies
Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N...
-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Company Website
Add To Watchlist
Bullboard (CSE:AGN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(40)
•••
StockDoctor101
X
View Profile
View Bullboard History
Post by
StockDoctor101
on Feb 01, 2023 3:12pm
AGN DMT study and interview
AGN looking to wrap up the DMT phase 1 study some time in June or July. Some solid data from the study in Q2 or Q3 this year could be huge for AGN. Will be on the lookout for more updates here. A
...more
(16)
•••
waves1
X
View Profile
View Bullboard History
Comment by
waves1
on Jan 31, 2023 5:08pm
RE:AGN CEO on Radius Research
Insightful interview - there is significant potential here as the phase 2a study showed a significant improvement in patients Ifenprodil is a novel first-in-class potential treatment for chronic
...more
(38)
•••
StockHawk1
X
View Profile
View Bullboard History
Post by
StockHawk1
on Jan 30, 2023 6:44pm
AGN CEO on Radius Research
Algernon Pharmaceuticals (AGN.c AGNPF) CEO, Christopher Moreau, on Radius Research giving an update on the company's Ifendprodil drug program which aim to test if the drug can help with chronic
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on Jan 30, 2023 5:59pm
Electratect.
https://electratect.com/about-om
(37)
•••
bmreed
X
View Profile
View Bullboard History
Post by
bmreed
on Jan 30, 2023 12:20pm
Update: $AGN CEO Chris Moreau - Chronic Cough Drug Program
News Update: Algernon Pharmaceuticals $AGN w CEO Christopher Moreau - Pitch, Deep Dive and Q&A - https://youtu.be/zpvV0-fELgc CEO Christopher Moreau provides an update on its
...more
(38)
•••
StockHawk1
X
View Profile
View Bullboard History
Post by
StockHawk1
on Jan 27, 2023 5:45pm
AGN CEO on new subsidiary
Algernon Pharmaceuticals (AGN.c AGNPF) CEO on the company's Phase 1 DMT Clinical Stroke Study, why the company decided to create a subsidiary for its DMT research (Algernon Nuro) and plans to
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on Jan 27, 2023 3:37pm
All Roads Lead To Dante's Inferno @ Algernon Pharmaceuticals
Take a look at the performance of Xortx Therapeutics (XRTX) today with its recent move towards a Phase III clinical trial. They're now at 52 week low with no bottom. The relevance is Xortx's
...more
(268)
•••
stockpatrol
X
View Profile
View Bullboard History
Post by
stockpatrol
on Jan 27, 2023 2:12pm
Algernon NeuroScience, a subsidiary of Algernon Pharmaceutic
Algernon NeuroScience, a subsidiary of Algernon Pharmaceuticals, has begun a Phase 1 clinical stroke study of DMT in the Netherlands, using a single-escalating dose design to determine a safe, non
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on Jan 26, 2023 9:10am
P.S.
My best guess is over the course of Moreau's management style the big winner in the entire equation is someone whom management (CEO, CSO, CFO) has had a blatant conflict of interest relationship
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on Jan 26, 2023 8:09am
A History Of Flip Flop Decisions Remains @ The Helm
@ Radius Research the Interviewer hits the correct number of 150% Dilution with a capital raise of 10M USD. Then turns right around and says a capital raise of 10M USD through Algernon Neuro only
...more
(127)
•••
SkywalkerofLuke
X
View Profile
View Bullboard History
Comment by
SkywalkerofLuke
on Jan 25, 2023 3:58pm
RE:AGN CEO on Radius Research regarding the DMT study update
Thanks for the share, great to hear the positive feedback from psychedelic funds on the study.
(16)
•••
waves1
X
View Profile
View Bullboard History
Post by
waves1
on Jan 25, 2023 3:08pm
AGN CEO on Radius Research regarding the DMT study update
AGN CEO Chris Moreau on Radius Research discussing the latest
...more
(16)
•••
waves1
X
View Profile
View Bullboard History
Comment by
waves1
on Jan 24, 2023 5:00pm
RE:DMT stroke trial commences with first patient dosed
There is significant potential here as AGN is taking a new approach to stroke treatment that greatly differs from the previous stroke drug treatments that failed. By focusing on promoting
...more
(26)
•••
XeniaTechie
X
View Profile
View Bullboard History
Post by
XeniaTechie
on Jan 24, 2023 3:17pm
DMT stroke trial commences with first patient dosed
Algernon announces they’ve dosed the first subject in the Phase 1 DMT clinical stroke study. This study is being conducted at the Centre for Human Drug Research in Leiden, Netherlands. The first part
...more
(127)
•••
SkywalkerofLuke
X
View Profile
View Bullboard History
Post by
SkywalkerofLuke
on Jan 23, 2023 5:07pm
Recent News
With the recent attention on AGN.c AGNPF’s Phase 1 DMT Clinical Stroke Study thought it’d be worth noting the recent developments from their Ifenprodil for chronic cough. Earlier this month they
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
EnviroGold Global Announces Appointment of Chief Operating Officer
Mining Player Sells Off Promising Project for Millions – Here's Where the Cash is Headed